Emerging Markets Report
November 26 2018 - 3:39PM
InvestorsHub NewsWire
StockLab Reports: Of Mice and
Men
Las Vegas, NV -- November 26, 2018 -- InvestorsHub
NewsWire -- Early stage biotechnology and pharmaceutical companies
often present a quandary for investors. The technology is generally
difficult to understand and investors just can't fully picture the
potential.
Except when that picture is an absolutely
stunning, must-see video from Wake Forest
University of a mouse paralyzed by Acute Lymphoblastic Leukemia
restored to mobility in two days by a drug now headed to the patent
portfolio of Spherix Incorporated (Nasdaq: SPEX). The drug,
"KPC34," is a next generation treatment designed to overcome
multiple resistance challenges and is also administered orally,
which is critical for patients who cannot tolerate repeated cycles
of chemotherapy. Importantly, the Company reports
that the drug
has doubled the mean survival time of patients
versus the current standard of care
treatments.
Read that
again. Doubled.
The brief video is jaw-dropping to say the least
and helps affirm the recent merger agreement of Spherix and CBM
BioPharma Inc, the private pharma company which obtains exclusive
drug development rights of drugs like KPC34 from top-flight
partners like Wake Forest University and the University of Texas at
Austin. Spherix
and CBM agreed to merge earlier this
month.
The merger will put the all-new Spherix right in
the middle of a rapidly expanding oncological drug market that
pharma industry publication DCAT Value Chain
Insights reports topped $133 billion globally in 2017, and
with spending on cancer drugs having doubled in the United States
since 2012. (Source: DCAT
Value Chain
Insights)
The same report also cites the IQVIA
Institute for Human Data Science which projects a
global market for oncology therapeutic medicines reaching $200
billion by 2022, averaging 10% to 13% growth during that time while
the U.S. market is expected to reach $100 billion with an average
growth rate of 12% to 15% for the same period. Additionally,
spending on cancer drugs in the U.S. is expected to double by 2022,
exceeding the nearly $50 billion in spending in
2017.
It warrants mention that Spherix is also
aggressively pursuing opportunities in the arena of pancreatic
cancer via another CBM project that will be added through the
merger. Developed at the University of Texas at Austin, the drug
DHA-dFdC has shown positive results in preclinical studies,
inhibiting pancreatic tumor growth in clinically relevant
transgenic mouse models. DHA-dFdC also overcomes tumor cell
resistance to current chemotherapeutic
drugs.
And while the mouse video is head turning,
inspiring even, it is potentially the tip of the iceberg for a
company which has come so very far, both in its science and in the
enormous increase of intellectual property now headed inside the
deal. Ultimately, Spherix's true value is unlikely to be fully
recognized until it has successfully changed oncological care
outcomes for
mice andmen.
About
Spherix
Spherix is committed to advancing innovation by
active participation in all areas of the patent market. Spherix
draws on portfolios of pioneering technology patents to partner
with and support product innovation. Spherix has acquired over 100
patents from Rockstar Consortium Inc., and several hundred patents
issued to Harris Corporation, covering a variety of methods and
components involved in switching, routing, networking, optical and
telecommunication sectors. The Spherix/CBM merger is pending
approval.
About CBM BioPharma,
Inc.
CBM BioPharma, Inc. (www.cbmbiopharmainc.com
) is a privately held pharmaceutical company with exclusive drug
development rights from world renowned partners like Wake Forest
University and University of Texas at Austin. The Company has a
team of leading drug development scientists who help advance their
technology. The CBM platform focuses on the treatment of numerous
cancers, including acute myeloid leukemia (AML), Acute
Lymphoblastic Leukemia (ALL) and pancreatic
cancer.
About
StockLab:
StockLab is powered by professional journalists
with two-decades of experience in public markets. Each subject
company that StockLab is contracted to cover is examined through a
macro/micro approach that reviews larger events for its primary
industry and how it might affect future market opportunities. First
tier sources will be studied, cited, and offered to readers.
Additionally, material events by the subject company will be noted
for the readers' consideration. We often rely on industry
experts, Forbes, Bloomberg, The Wall Street
Journal and other periodicals of established pedigree which
have no relationship to the covered company
whatsoever.
Statements herein may contain forward-looking
statements and are subject to significant risks and uncertainties
affecting results. StockLab is the property of Integrity Media Inc.
(IMI). IMI provides no assurance as to the subject company's plans
or ability to effect proposed actions and cannot project
capabilities, intent, resources, or experience. The subject company
has reviewed and approved this report. This report is neither a
solicitation to buy nor offer to sell securities and is for
informational purposes only and shouldn't be used as basis for
investment decisions. IMI isn't an investment advisor, analyst or
licensed broker dealer and this report isn't investment advice. IMI
has been paid $1,500 for this report by Hayden IR on behalf of and
for the benefit of Spherix Incorporated. Paid reports constitute a
conflict of interest as to IMI's ability to remain objective in
communication regarding subject companies. Other articles linked to
herein have not been individually vetted for
accuracy.
To have your company featured in a StockLab report
please use the contact info
below:
Integrity Media
www.StockLab.com &
www.IntegrityIR.com
info@integrityir.com
(888)
216-3595
https://www.smarteranalyst.com/brief/the-ceo-of-spherix-inc-spex-is-buying-shares/
Disclaimer
What is the Nature of the Information We
Distribute?
Emerging Markets Consulting, LLC ("EMC"), its
principals, affiliates, representatives, subcontractors or agents
(hereafter referred to as "EMC" or "we" or "us") prepare and/or
assist others in preparing and publishing oral and written
information about public companies ( referred to herein
individually as the "Profiled Company" ) and their securities (the
"Securities"), including corporate and business profiles, alerts,
summaries, reports, and press releases (hereafter referred to as
the "Information") through: (a) double opt-in spam compliant
emails; (c) mail and courier; (d) EMC's websites profiling the
Profiled Company; and (e) otherwise through the worldwide web. In
certain cases, we are merely a distributor of such publications,
i.e. a Profiled Company's press
release.
Nature of the
Information
We generally only provide favorable information and
no negative information; thus, the Information is incomplete and we
urge you to avail yourself of all reliable sources of information,
including sec.gov, otcmarkets.com and
Google.
Due
Diligence?
We conduct no due diligence regarding the
Information.
What we are
Not
We are not independent and the Information should
be construed as a paid advertisement. We do not conduct research or
evaluate if the Information is true, accurate or complete. The
Information should not be construed as a recommendation to purchase
or sell the securities of the Profiled Company or as providing any
information that may be construed as investment advice. We are not
and do not act in the capacity of: (a) an investment advisor; (b) a
stock picker; (c) a securities trading expert; (d) a securities
analyst; (e) a financial analyst; (f) one that provides stock
recommendations, price targets, buy, sell or hold recommendations.
Rather, we only introduce a company to the readers of our
publications as a starting point for investigating the securities
and the Profiled Company through publicly available sources. EMC
does not endorse, independently verify, or assert the truthfulness,
completeness, accuracy or reliability of the Information; as such,
the Information is presented in an "as is" format and the
Recipients should not rely on the data or information contained in
the Information in making an investment decision and should conduct
their own research of the Profiled
Company.
Beware of Revenue
Projections
The Recipients of the Information should be
especially cautious about any revenue predictions, projected
revenues, revenue expectations or revenue estimates (the "Revenue
Projections") because: (a) we conduct no due diligence whatsoever
on whether the Revenue Projections have a foundational basis; (b)
the Revenue Projections may not be in accordance with US Generally
Accepted Accounting Principles or SEC guidelines for projections;
(c) the assumptions upon which the projections are being made may
lack a foundational basis; (d)) the Revenue Projections may be
inherently unreliable because they are subject to future
events.
Cautionary Advice on Use of the
Information
The Information is disseminated to broker-dealers,
members of the public, readers of our website, and the financial
community (collectively the "Recipients") at the direction of the
Profiled Company or other investor relations firms or third-party
shareholders of the Profiled Company or firm hired by the Profiled
Company for which we provide subcontracting services or through
social media, including Facebook, Twitter, LinkedIn and blog spots.
The Information should only be used by as a beginning point for
further investigation into the Profiled Company and its securities
because EMC: (a) only presents neutral or positive information
regarding the Profiled Company and its business; (b) does not
present the risks or negative aspects associated with the Profiled
Company or its securities; and (c) the Information is wholly
inadequate to formulate any investment decision. As such, we
strongly advise against making any investment decisions solely
based on the Information. It is imperative that you consult with
your professional advisor, financial adviser, financial planner,
registered broker or attorney regarding the advisability of
investing in any securities, especially penny stocks. In addition,
you should consult with government or other websites that are
available free of charge at www.sec.gov, www.otcmarkets.com, Google, or other sources that
offer specific business and financial information about the
Profiled Company, investment guides and valuable information
pertaining to penny stocks, penny stock frauds and penny stock
investment risks. Where applicable, you should review the quarterly
(Form 10-Q) and annual (Form 10-K) financial and disclosure reports
available at www.sec.gov. For those companies that are not SEC
reporting companies, you should review the quarterly and annual
reports available for your review at www.otcmarkets.com.
Payment for our
Services
We are paid for our services in either money or
securities or a combination of cash and securities compensation.
The publicly traded companies or third-party shareholders or other
publishers or investor relations firms that subcontract with us for
the services that they have directly contracted for with a publicly
traded company or a third-party shareholder pay us for our
advertisements
Our Trading
Activities
Pursuant to an agreement between EMC and a Profiled
Company, EMC always receives compensation from the Profiled Company
or third-party shareholder or other investor relations firm in cash
and/or securities compensation of the Profiled Company for the
services that EMC performs in connection with preparation and/or
dissemination of the Information, EMC regularly and routinely sells
the Profiled Company's securities before, during and after its
dissemination of the Information regarding the Profiled Company
(most frequently during the dissemination of the Information),
which may result in substantial profits to EMC. EMC may purchase
shares of the Profiled Company before, during and after
dissemination of the Information disseminated by EMC, which may
result in substantial profits to EMC. ; EMC's dissemination of the
Information may result in increases in the Profiled Company's
securities total trading volume or in the purchase volume of the
Profiled Company's securities, enabling EMC to sell its Securities
at a profit from the securities compensation it receives for
providing services involving publications of the Profiled Company.
EMC's sale of the Profiled Company's securities concurrently with
the dissemination of the Information, including the Profiled
Company's profile, may enable EMC to sell at a higher price for
such shares, and may result in a diminished value to those buying
the Profiled Company's securities because of EMC’s selling
activities
Conflicts of
Interest
Our advertisements involve an actual conflict of
interest, since we receive compensation in the very securities we
are promoting and then sell the securities during our advertorial
activities or thereafter. The Profiled Company or investor
relations firm or third-party shareholder from whom we receive
compensation also has an actual conflict of interest since they pay
us securities compensation for advertising services and then may
sell their own shares of the Profiled Company while we are
publishing the Information about the Profiled Company or its
securities
Forward Looking
Statements
Statements contained in the Information that are
not historical facts are forward looking statements that involve
risks and uncertainties and may be identified using terminology
such as "believes", "expects", "may", ""will", or "should"", or
"anticipates". Such statements should be read as being applicable
to all related forward looking statements wherever they appear in
any of the Information. The actual results of a Profiled Company's
operations, financial condition or other aspects of its business
could differ materially from those discussed in the
Information.
No
Warranties
We do not make any implied or express warranties
regarding the Information -- you should not solely rely upon the
Information; rather, again you should use the Information and/or
its securities as an initial introduction to the Profiled Company
to initiate an investigation into a Profiled Company through, among
other sources, information and reports available at the
above-listed websites.
Risks
Use of the Information as well as any investment in
micro-cap or penny stock securities is subject to the following
risks:
- EMC is not a
registered investment advisor or registered securities broker
dealer and no information contained within the Information should
be construed as investment advice or as a solicitation to offer,
purchase or sell the Securities; therefore, you should never use
the Information as the only basis upon which you make an investment
decision and understand that the use of our Information does not
provide you with the benefits of receiving advice from a registered
investment adviser or registered representative or a broker or
dealer and/or conducting an in-depth investigation of a Profiled
Company.
- EMC does not
provide stock recommendations; as such, none of the Information
should be construed directly or indirectly or explicitly or
impliedly, as stock recommendations and you should rely upon your
professional adviser regarding such matters, including your
registered broker, investment adviser or other qualified financial
adviser.
- EMC does not
endorse, independently verify or assert the truthfulness,
completeness, accuracy or reliability of the Information and
conducts no due diligence whatsoever of the Profiled
Company.
- Penny stocks are
subject to the SEC's penny stock rules, which may cause
difficulties in liquidating micro-cap
securities;
- Penny stocks by
their very nature involve a high degree of risk and may involve the
loss of one's entire
investment.
- Energy, biotech,
and other companies are subject to increased regulations, which
subject them to material costs and possible fines and
liabilities.
- Because we may
sell material amounts of the Securities during the dissemination of
the Information, shortly thereafter, or at any time, our selling
activities may negatively cause price volatility, stock price
declines and/or increased/decreased selling
volume.
- Because we may
purchase material amounts of the Securities in the open market
before, during or after the dissemination of the Information, such
activities may cause price volatility, stock price increases or
declines or increased/decreased
volume.
- Because we only
present positive or neutral information regarding the Profiled
Company and do not provide negative information in our Profiles, it
is all the more important that you conduct further investigation of
the Profiled Company, consult with outside sources (i.e. www.sec.gov) and consult with your professional
adviser. Additionally, because we only present selected positive or
neutral information, when conducting your investigation into the
Profiled Company and its securities you should determine what
information is material or
immaterial.
- Because EMC is a
Shareholder of the Profiled Company, it has an inherent conflict of
interest with the Recipients, wherein EMC may favor their own
interests over that of the Recipients because EMC may be selling
its own securities of the Profiled Company during its publication
and/or distribution of the Information or at any
time.
- The buying and
selling of the Securities by EMC may negatively affect the volume
or price of the Securities, including price declines or price and
volume volatility.
- Penny stock
securities are often thinly traded, in which case you may have
difficulties in liquidating your
securities.
- Penny stock
securities by their very nature involve an extremely high degree of
risk.
- Because the
Securities are penny stocks they are subject to the Securities and
Exchange Commission's penny stock rules; as such, any investment in
the Securities involves a high degree of risk and it may be
difficult for any investor or Shareholder to resell the
Securities.
- An investment in
the Profiled Company's Securities could result in the loss of some
or all an investment in the Profiled Company's
Securities.
- The issuance of
the Securities to EMC may cause shareholders and/or investors of
the Profiled Company to experience immediate and substantial
dilution of their holdings and/or investments in the Profiled
Company
- Future securities
issuances to EMC for services may also result in a reduction of (i)
the book value or market price of the Profiled Company's
securities, (ii) shareholder voting power; and (iii) each
shareholder's proportionate ownership of any Profiled
Company.
- You should
consider whether the Profiled Company is a development stage
company or has little or no operations or no revenues or assets,
the conditions of which may increase the risk investment level of
investing in the Profiled
Company.
- You should
consider the financial condition of the Profiled Company in your
analysis by accessing such information from www.sec.gov or www.otcmarkets.com; if such financial
information is unavailable from either one of these sites, the risk
investment level of investing in any such Profiled Company will be
increased.
- Many of the
companies are subject to numerous risks particular to the industry
that they engage in.
- We conduct no due
diligence whatsoever regarding: (a) the Issuer; (b) the third-party
shareholder; and (c) the relationship, if any, between the
third-party shareholder and the
Issuer;
- Our trading
activities described above may cause: (a) significant volatility in
the Issuer's; (b) price declines from our selling activities; (c)
an unrealistic report of trading volume, without denoting publicly
that we are the primary seller; (d) permit us to make substantial
profits while we are disseminating profiles or information about
the issuer, yet may result in a diminished value of the Profiled
Company's Securities
- We conduct no due
diligence on the press releases or profiles we receive from OTC
Markets News Service or other publicly available source, nor do we
conduct due diligence on any other information we disseminate to
the public.
- Penny stocks are
subject to the SEC's penny stock rules and subject broker-dealers
to customer suitability rules and other requirements, which may
lead to low volume in the securities and/or difficulties in selling
the shares.
- Many of the
stocks of the Profiled Company qualify as "penny stocks" under the
Securities and Exchange Commission's ("SEC") penny stock rules and
regulations because, among other things, they have a price of less
than $5.00 per share. Penny stocks are subject to material risks
that you should be acutely aware of, as detailed
below.
- We do not assume
any responsibility for forward-looking statements nor do we assume
any responsibility for updating forward-looking
statements
- Use of this
information is at your own risk and is presented only on an "as is"
basis - in other words, you must conduct your own analysis of the
risks associated with use of the Information, including its
accuracy or
reliability
- Many penny stocks
are thinly traded, which may lead to difficulties in selling your
securities and extreme price
volatility.
- Penny stock
companies are often subject to extreme regulatory oversight in the
industry that they participate
in.
- Penny stock
companies are often subject to extreme competition and most
frequently have less brand name recognition, operational and
personnel resources, technical resources, capital resources, or
financing sources.
- There is no
"right time" to purchase or sell penny stocks or set of factors
making it advisable to purchase a Profiled Company's securities
"now", since at any time such stocks may be subject to price
volatility, stock manipulation forces and other negative market
forces.
- A Profiled
Company may have negative signs on the otcmarkets.com website that indicate various risks of
investing in that individual issuer, as follows: (i) "Limited
Information" for companies with financial reporting problems,
economic distress, or that are unwilling to file required reports
with the Pink Sheets; (ii) "Pink Sheets - No Information", which
indicates companies that are unable or unwilling to provide
disclosure to the public markets, to the SEC or the Pink Sheets;
and (iii) "Caveat Emptor", signifying "Buyer Beware" that there is
a public interest concern associated with a company's illegal spam
campaign, questionable stock promotion, known investigation of a
company's fraudulent activity or its insiders, regulatory
suspensions or disruptive corporate
actions.
- The Issuer may be
delinquent in its filings with the Securities and Exchange
Commission or at otcmarkets.com, which you will be able to determine by
accessing the websites at www.sec.gov or www.otcmarkets.com.
- The stock price
and trading volume of any Issuer that we advertise may increase
significantly because of our dissemination of the Information and
then significantly decrease because of our or others selling
significant or massive quantities of an
Issuer;
- Many penny stock
companies are subject to risks pertaining to the development stage
nature of their business, including that they have failed to
provide a proof of concept to their technology or business or their
business plan has little if any merit
whatsoever.
- Many penny stock
companies need financing, which they may be unable to obtain on
favorable terms or at
all.
- Our advertising
activities may cause trading volume of a Profiled Company's
securities to temporarily increase by hundreds or thousands of
percent, yet such trading volume may cease at any one
time;
- Our advertising
activities may cause trading volume in Issuers to materially
increase, yet such trading volume may cease at any one time,
especially if we cease disseminating Information about the Issuers,
which will cause difficulties in selling your securities or may be
an unrealistic indicator of interest in the Issuer's
securities.
- The Information
has no predictive value whatsoever of the future stock price of the
Profiled Company's securities or its ability to be successful in
its business
objectives.
- Should the SEC
determine that inadequate information or irregularities have
occurred with a Penny Stock Issuer, they may issue a trading
suspension, which will suspend trading in the Issuer's securities
and may for all intents and purposes permanently cease trading
because broker-dealers may not accept trades in that Issuer’s
securities.
- The press
releases, issuer profiles and information we provide represent only
a small amount of information regarding the Issuer, which is
insufficient to formulate an investment decision; as such, that
information should only be a starting point from which you conduct
an in-depth investigation of the issuer from available public
sources, such as www.sec.gov, www.otcmarkets.com, yahoofinance.com, www.google.com and other available public sources;
and
Conduct an In-Depth
Investigation
You should conduct an in-depth investigation of the
Profiled Company and its securities from the above or any other
credible available sources, especially because we only present
positive information and limited specific information which is an
insufficient basis to invest in any stock, yet alone a penny stock;
accordingly, you should proceed with an investigation to determine,
among other things, information pertaining to the issuer's
financial condition, operations, business model, and risks involved
in the issuer's business.
Compensation
Disclosure
Section 17(b) of the Securities Act of 1933
requires that any person that uses the mails to publish, give
publicity to, or circulate any publication or communication that
describes a security in return for consideration received or to be
received directly or indirectly from an issuer, underwriter, or
dealer, must fully disclose the type of consideration (i.e. cash,
free trading stock, restricted stock, stock options, stock
warrants) and the specific amount of the consideration. In
connection therewith, EMC has received the following compensation
and/or has an agreement to receive in the future certain
compensation, as described
below.
EMC has been paid $35,000 from Spherix
Inc,
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Sep 2023 to Sep 2024
See More Message Board Posts